Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epallolitovorizumab
- Development stage
- Unknown
- Lead developer
- Sir Run-Run Shaw Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Epallolitovorizumab is an anti-tumor monoclonal antibody currently under clinical investigation as a neoadjuvant therapy for locally advanced cervical cancer. Developed by Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, it is being evaluated in Phase 2 clinical trials in combination with standard chemotherapy agents cisplatin and paclitaxel. The drug is intended to improve surgical outcomes and survival in patients with AJCC stage T1b3, T2a2, or T2b cervical cancer by reducing tumor burden prior to radical hysterectomy. While the specific molecular target is not explicitly detailed in early registry records, its nomenclature and clinical context suggest it functions as an immune checkpoint inhibitor or a targeted anti-tumor biologic.
- Other names
- epallolitovorizumab
Beyond the preview
Go deeper on epallolitovorizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epallolitovorizumab.